News in Brief
Life Sciences - Dec 2
Sea urchins and social distance: 12 UChicago students study at the Marine Biological Laboratory
Sea urchins and social distance: 12 UChicago students study at the Marine Biological Laboratory
Pedagogy - Dec 2
New poll reveals more than 70% of parents in the UK have concerns over children’s increasing online exposure during the pandemic
New poll reveals more than 70% of parents in the UK have concerns over children’s increasing online exposure during the pandemic
Social Sciences - Dec 2
UCL leads £2m international policy initiative to reduce social impacts of COVID-19
UCL leads £2m international policy initiative to reduce social impacts of COVID-19
Economics - Dec 2
No country ’immune’ to COVID-19 economic shock, but Asian nations will bounce back faster
No country ’immune’ to COVID-19 economic shock, but Asian nations will bounce back faster
Health - Dec 2
Roche receives FDA Emergency Use Authorization for new test to measure the level of SARS-CoV-2 antibodies
Roche receives FDA Emergency Use Authorization for new test to measure the level of SARS-CoV-2 antibodies
news
« BACK
Health - Pharmacology - 01.12.2020 
Deciphering the energetic code of cells for better anticancer therapies
A procedure that may help personalise anticancer therapies has just been developed by the CNRS, INSERM, and Aix-Marseille University scientists at the Centre d'Immunologie de Marseille-Luminy, in association with colleagues from the University of California San Francisco and the Marseille Public University Hospital System (AP-HM), with support from Canceropôle Provence-Alpes-Côte d'Azur.
Health - Pharmacology - 01.12.2020
Health - Pharmacology - 01.12.2020 
Scientists identify warning signs over effectiveness of HIV ’wonder drug’ in sub-Saharan Africa
Dolutegravir, the current first-line treatment for HIV, may not be as effective as hoped in sub-Saharan Africa, suggests new research published on World AIDS Day. The study finds that this so-called 'wonder drug' may be less effective in patients resistant to older drugs. Dolutegravir was very much seen as a 'wonder drug', but our study suggests it might not be as effective in a significant number of patients who are resistant to another important class of antiretroviral drugs Ravi Gupta As HIV copies itself and replicates, it can develop errors, or 'mutations', in its genetic code (its RNA).
Pharmacology - Health - 01.12.2020 
Environmental exposures affect therapeutic drugs
High-resolution mass spectrometry promotes new methods for analysis Humans are exposed to various environmental or dietary molecules that can attenuate or even increase the effect of therapeutic drugs. Studies on the industrial chemical bisphenol A and the phytoestrogen genistein, for example, have shown drug-exposome interactions.
Pharmacology - Health - 30.11.2020 
New cancer-fighting method leverages the mechanical force of T cells
Scientists have developed a cancer treatment method that destroys tumor cells using the mechanical force of our bodies- own T cells. They have just completed a proof of concept for their novel immunotherapy approach. Immunotherapy is a promising weapon in the fight against cancer. It has proven to be much more effective than chemotherapy and radiotherapy in treatment of some cancers.
Pharmacology - Psychology - 27.11.2020
Life Sciences - Pharmacology - 27.11.2020
Health - Pharmacology - 25.11.2020
Pharmacology - Health - 25.11.2020
Health - Pharmacology - 25.11.2020 
Iron Infusion Proves Effective to Treat Anaemia in Rural Africa
Iron-deficiency anaemia is a major concern in low-income settings, especially for women. In a new study by the Swiss Tropical and Public Health Institute (Swiss TPH) and partners published yesterday in The Lancet Global Health, researchers found that iron infusion was feasible, safe and in contrast to the standard iron-deficiency anaemia treatment of oral iron tablets, highly effective in Tanzania.
Health - Pharmacology - 24.11.2020
Health - Pharmacology - 23.11.2020
Pharmacology - Chemistry - 19.11.2020
Pharmacology - Health - 19.11.2020
Pharmacology - Health - 19.11.2020
Health - Pharmacology - 18.11.2020
Health - Pharmacology - 17.11.2020
Health - Pharmacology - 17.11.2020
Health - Pharmacology - 16.11.2020
Pharmacology - Health - 13.11.2020
Pharmacology
Results 1 - 20 of 1125.
A procedure that may help personalise anticancer therapies has just been developed by the CNRS, INSERM, and Aix-Marseille University scientists at the Centre d'Immunologie de Marseille-Luminy, in association with colleagues from the University of California San Francisco and the Marseille Public University Hospital System (AP-HM), with support from Canceropôle Provence-Alpes-Côte d'Azur.
UCLA, UCSF gain FDA approval for prostate cancer imaging technique
Method is a 'game changer' that should become the standard of care, say researchers from both universities who validated its effectiveness Method is a 'game changer' that should become the standard of care, say researchers from both universities who validated its effectiveness The University of California's two nationally ranked medical centers, UCSF and UCLA, and their nuclear medicine teams have obtained approval from the U.S. Fo
Method is a 'game changer' that should become the standard of care, say researchers from both universities who validated its effectiveness Method is a 'game changer' that should become the standard of care, say researchers from both universities who validated its effectiveness The University of California's two nationally ranked medical centers, UCSF and UCLA, and their nuclear medicine teams have obtained approval from the U.S. Fo
Dolutegravir, the current first-line treatment for HIV, may not be as effective as hoped in sub-Saharan Africa, suggests new research published on World AIDS Day. The study finds that this so-called 'wonder drug' may be less effective in patients resistant to older drugs. Dolutegravir was very much seen as a 'wonder drug', but our study suggests it might not be as effective in a significant number of patients who are resistant to another important class of antiretroviral drugs Ravi Gupta As HIV copies itself and replicates, it can develop errors, or 'mutations', in its genetic code (its RNA).
High-resolution mass spectrometry promotes new methods for analysis Humans are exposed to various environmental or dietary molecules that can attenuate or even increase the effect of therapeutic drugs. Studies on the industrial chemical bisphenol A and the phytoestrogen genistein, for example, have shown drug-exposome interactions.
Scientists have developed a cancer treatment method that destroys tumor cells using the mechanical force of our bodies- own T cells. They have just completed a proof of concept for their novel immunotherapy approach. Immunotherapy is a promising weapon in the fight against cancer. It has proven to be much more effective than chemotherapy and radiotherapy in treatment of some cancers.
Treatment for drug addiction - how do patients cope in lockdown?
There are encouraging signs that people in treatment for drug addiction can manage their medication when they are entrusted with a substantial quantity of opiate substitutes and told to take it in small daily doses, finds a new 'early insight' report from researchers at the Universities of Bristol and Bath.
There are encouraging signs that people in treatment for drug addiction can manage their medication when they are entrusted with a substantial quantity of opiate substitutes and told to take it in small daily doses, finds a new 'early insight' report from researchers at the Universities of Bristol and Bath.
Identificat un mecanisme cerebral essencial per a la capacitat de recordar
(C) Image of the hippocampus (blue cells) showing the innervation it receives from medial septum inhibitor axons (red). Under normal conditions, the innervation of the medial septum (GABA) limits the activation of interneurons (PV) in the hippocampus during the memories, thus allowing the reactivation of neurons (pyr) that encode memory.
(C) Image of the hippocampus (blue cells) showing the innervation it receives from medial septum inhibitor axons (red). Under normal conditions, the innervation of the medial septum (GABA) limits the activation of interneurons (PV) in the hippocampus during the memories, thus allowing the reactivation of neurons (pyr) that encode memory.
New immunotherapy shows promise against rare childhood cancer
A novel CAR T-cell therapy developed by researchers at UCL and designed to target cancerous tumours, has shown promising early results in children with neuroblastoma, a rare form of childhood cancer. For this proof-of-principle study, researchers at the UCL Great Ormond Street Institute for Child Health (GOS ICH) and the UCL Cancer Institute modified the patient's own T-cells (a type of immune cell), equipping them to recognise and kill neuroblastoma tumour cells.
A novel CAR T-cell therapy developed by researchers at UCL and designed to target cancerous tumours, has shown promising early results in children with neuroblastoma, a rare form of childhood cancer. For this proof-of-principle study, researchers at the UCL Great Ormond Street Institute for Child Health (GOS ICH) and the UCL Cancer Institute modified the patient's own T-cells (a type of immune cell), equipping them to recognise and kill neuroblastoma tumour cells.
New breakthrough in the treatment of rheumatoid arthritis
People with Rheumatoid Arthritis (RA) could soon benefit from a new drug treatment that not only suppresses inflammation but also significantly reduces patient reported pain scores. Otilimab is a monoclonal antibody, biologic drug, which targets and suppresses the inflammatory cytokine GM-CSF. In a multicentre, dose-ranging trial, led by Professor Chris Buckley at the Universities of Oxford and Birmingham, and sponsored by the Pharmaceutical company GSK, researchers explored the clinical effects of otilimab to prevent inflammation, tissue damage and pain in people with RA.
People with Rheumatoid Arthritis (RA) could soon benefit from a new drug treatment that not only suppresses inflammation but also significantly reduces patient reported pain scores. Otilimab is a monoclonal antibody, biologic drug, which targets and suppresses the inflammatory cytokine GM-CSF. In a multicentre, dose-ranging trial, led by Professor Chris Buckley at the Universities of Oxford and Birmingham, and sponsored by the Pharmaceutical company GSK, researchers explored the clinical effects of otilimab to prevent inflammation, tissue damage and pain in people with RA.
Iron-deficiency anaemia is a major concern in low-income settings, especially for women. In a new study by the Swiss Tropical and Public Health Institute (Swiss TPH) and partners published yesterday in The Lancet Global Health, researchers found that iron infusion was feasible, safe and in contrast to the standard iron-deficiency anaemia treatment of oral iron tablets, highly effective in Tanzania.
Rhythm and bleughs: how changes in our stomach’s rhythms steer us away from disgusting sights
Does the sight of maggots squirming in rotten food make you look away in disgust? The phrase 'makes my stomach turn' takes on a new meaning today as researchers at the University of Cambridge reveal that changes in the rhythm of our stomachs prompt us to look away from disgusting images.
Does the sight of maggots squirming in rotten food make you look away in disgust? The phrase 'makes my stomach turn' takes on a new meaning today as researchers at the University of Cambridge reveal that changes in the rhythm of our stomachs prompt us to look away from disgusting images.
New nanotechology design provides hope for personalized ’vaccination’ to treat cancer
One of the key challenges in developing effective cancer treatments is how different cancer cells are. This variation makes it difficult for the immune system to recognize and actively fight against tumors. Now, however, new advances in nanotechnology are making it possible to deliver targeted, personalized "vaccines" to treat cancer.
One of the key challenges in developing effective cancer treatments is how different cancer cells are. This variation makes it difficult for the immune system to recognize and actively fight against tumors. Now, however, new advances in nanotechnology are making it possible to deliver targeted, personalized "vaccines" to treat cancer.
Clearing the Course for Glycans in Development of Flu Drugs
Researchers demonstrate molecular binding mechanism that could change approach to designing influenza treatments There is no hole-in-one drug treatment when it comes to the flu, but that doesn't stop scientists from trying to sink one. Especially since as many as one in five Americans gets the flu. The reported estimated cost of this illness is $10 billion each year in medical expenses and another $16 billion in lost earnings in America alone, according to researchers at UC San Diego.
Researchers demonstrate molecular binding mechanism that could change approach to designing influenza treatments There is no hole-in-one drug treatment when it comes to the flu, but that doesn't stop scientists from trying to sink one. Especially since as many as one in five Americans gets the flu. The reported estimated cost of this illness is $10 billion each year in medical expenses and another $16 billion in lost earnings in America alone, according to researchers at UC San Diego.
New effective and safe antifungal isolated from sea squirt microbiome
Pharmacy professor Tim Bugni has led a UW-Madison effort to identify novel antimicrobials from understudied ecosystems. School of Pharmacy By combing the ocean for antimicrobials, scientists at the University of Wisconsin-Madison have discovered a new antifungal compound that efficiently targets multi-drug-resistant strains of deadly fungi without toxic side effects in mice.
Pharmacy professor Tim Bugni has led a UW-Madison effort to identify novel antimicrobials from understudied ecosystems. School of Pharmacy By combing the ocean for antimicrobials, scientists at the University of Wisconsin-Madison have discovered a new antifungal compound that efficiently targets multi-drug-resistant strains of deadly fungi without toxic side effects in mice.
Drug eases recovery for those with severe alcohol withdrawal
A drug once used to treat high blood pressure can help alcoholics with withdrawal symptoms reduce or eliminate their drinking, Yale University researchers report Nov. 19 in the American Journal of Psychiatry. In a double-blind study, researchers gave the drug prazosin or a placebo to 100 people entering outpatient treatment after being diagnosed with alcohol use disorder.
A drug once used to treat high blood pressure can help alcoholics with withdrawal symptoms reduce or eliminate their drinking, Yale University researchers report Nov. 19 in the American Journal of Psychiatry. In a double-blind study, researchers gave the drug prazosin or a placebo to 100 people entering outpatient treatment after being diagnosed with alcohol use disorder.
Alzheimer’s disease drug may help fight against antibiotic resistance
An experimental Alzheimer's disease treatment is proving effective at treating some of the most persistent, life-threatening antibiotic-resistant bacteria. Researchers from The University of Queensland, The University of Melbourne and Griffith University have discovered that the drug called PBT2 is effective at disrupting and killing a class of bacteria - known as Gram-negative bacteria - that cause infections such as pneumonia, bloodstream infections and meningitis.
An experimental Alzheimer's disease treatment is proving effective at treating some of the most persistent, life-threatening antibiotic-resistant bacteria. Researchers from The University of Queensland, The University of Melbourne and Griffith University have discovered that the drug called PBT2 is effective at disrupting and killing a class of bacteria - known as Gram-negative bacteria - that cause infections such as pneumonia, bloodstream infections and meningitis.
Rapid point-of-care testing during and after COVID-19 - how widely should it be used?
Even before the COVID-19 pandemic, the point-of-care testing industry was investing millions of pounds to develop rapid tests to tell us the cause of respiratory infections. The pandemic has accelerated this process. In an editorial published in the British Journal of General Practice today [17 November], researchers from the University of Bristol's Centre for Academic Primary Care ask if we know enough about these tests to merit their widespread use in primary care.
Even before the COVID-19 pandemic, the point-of-care testing industry was investing millions of pounds to develop rapid tests to tell us the cause of respiratory infections. The pandemic has accelerated this process. In an editorial published in the British Journal of General Practice today [17 November], researchers from the University of Bristol's Centre for Academic Primary Care ask if we know enough about these tests to merit their widespread use in primary care.
The Zayed Centre for Research celebrates first anniversary
With a vision to develop new treatments and cures for seriously ill children, the Zayed Centre for Research into Rare Disease in Children, is celebrating its first year of work and achievements. Run jointly by UCL and Great Ormond Street Hospital (GOSH) the purpose-built Zayed Centre for Research (ZCR) brings together pioneering research and clinical care under one roof - a world first for paediatric medicine.
With a vision to develop new treatments and cures for seriously ill children, the Zayed Centre for Research into Rare Disease in Children, is celebrating its first year of work and achievements. Run jointly by UCL and Great Ormond Street Hospital (GOSH) the purpose-built Zayed Centre for Research (ZCR) brings together pioneering research and clinical care under one roof - a world first for paediatric medicine.
UofG researchers report how novel diabetes drugs work to improve the prognosis for patients with heart failure
Scientists at the University of Glasgow have furthered the understanding of how novel diabetes drugs can improve prognosis for patients with heart failure. The results of the SUGAR-DM-HF trial - published in Circulation and presented to the American Heart Association - showed that the drug empagliflozin, originally a treatment for patients with type 2 diabetes, was able to significantly reduce the size of abnormally large hearts, which helps explain how they reduce the risk of hospitalisation and cardiovascular death in patients with heart failure.
Scientists at the University of Glasgow have furthered the understanding of how novel diabetes drugs can improve prognosis for patients with heart failure. The results of the SUGAR-DM-HF trial - published in Circulation and presented to the American Heart Association - showed that the drug empagliflozin, originally a treatment for patients with type 2 diabetes, was able to significantly reduce the size of abnormally large hearts, which helps explain how they reduce the risk of hospitalisation and cardiovascular death in patients with heart failure.
Analysis: Believing in conspiracies goes hand in hand with vaccine hesitancy
Dr Gul Deniz Salali, Lecturer in Evolutionary Anthropology and Medicine at UCL, discusses new research which confirms findings from before the pandemic that vaccine hesitancy often coincides with broader anti-scientific thinking. While developing an effective vaccine probably won't bring an immediate end to the pandemic, it's clear that things can't begin to return to normal without one.
Dr Gul Deniz Salali, Lecturer in Evolutionary Anthropology and Medicine at UCL, discusses new research which confirms findings from before the pandemic that vaccine hesitancy often coincides with broader anti-scientific thinking. While developing an effective vaccine probably won't bring an immediate end to the pandemic, it's clear that things can't begin to return to normal without one.
News in Brief
Life Sciences - Dec 2
Sea urchins and social distance: 12 UChicago students study at the Marine Biological Laboratory
Sea urchins and social distance: 12 UChicago students study at the Marine Biological Laboratory
Pedagogy - Dec 2
New poll reveals more than 70% of parents in the UK have concerns over children’s increasing online exposure during the pandemic
New poll reveals more than 70% of parents in the UK have concerns over children’s increasing online exposure during the pandemic
Social Sciences - Dec 2
UCL leads £2m international policy initiative to reduce social impacts of COVID-19
UCL leads £2m international policy initiative to reduce social impacts of COVID-19
Economics - Dec 2
No country ’immune’ to COVID-19 economic shock, but Asian nations will bounce back faster
No country ’immune’ to COVID-19 economic shock, but Asian nations will bounce back faster
Health - Dec 2
Roche receives FDA Emergency Use Authorization for new test to measure the level of SARS-CoV-2 antibodies
Roche receives FDA Emergency Use Authorization for new test to measure the level of SARS-CoV-2 antibodies